



Andrew Liu to Join SanBio as Chief Strategy Officer

Tokyo, Japan and Mountain View, Calif. – June 1, 2022 – The SanBio Group (SanBio Co., Ltd. and subsidiaries SanBio, Inc. and SanBio Asia Pte. Ltd.) hereby announces that Mr. Andrew Liu joined the Group as a new Chief Strategy Officer on May 16, 2022.

At investment bank JPMorgan and private equity funds, Andrew spearheaded many successful projects in fund raising, M&A and investments. As head of Corporate Development at Santen Pharmaceutical Co., Ltd. and listed Chinese company Chengdu Kanghong Pharmaceutical Group Co., Ltd., he was responsible for business development, corporate planning, and product portfolio strategy, creating corporate value by leading pipeline out-licensing and in-licensing, business acquisitions, investment in biotech startups, and business reorganization.

In March 2022, the SanBio Group filed its first application for manufacture and marketing approval with Japan's Ministry of Health, Labour, and Welfare, for the regenerative medicine product SB623 as a treatment for chronic motor deficit from traumatic brain injury. In addition to laying the foundations for a commercial launch of SB623 in Japan, the SanBio Group intends to maximize corporate value through international market rollout, leveraging Andrew's wealth of experience in strategic management and business development.

Andrew commented as follows on joining the Company: "I'm thrilled to take part in SanBio's efforts to address central nervous system disorders, an area of high unmet medical need, by developing regenerative cell therapies, creating a new pharmaceutical segment. I intend to fully leverage my experience and make every effort to assist SanBio in realizing its vision of becoming a global leader in regenerative medicine."

Keita Mori, CEO of the Company commented as follows: "We are pleased to welcome on board Andrew, who has strong experience and track record in strategic management and business development at pharmaceutical companies. We are confident that Andrew's experience and capabilities will greatly assist SanBio to accelerate delivering SB623 and other investigational drugs to patients, and be a driving force in the company's development."

About SanBio

SanBio is engaged in the regenerative cell medicine business, spanning research, development, manufacture, and sales of regenerative cell medicines. SanBio targets patients with high unmet medical needs that cannot be addressed by existing medical treatments, mainly in diseases of the

central nervous system. SanBio is headquartered in Tokyo, Japan and has subsidiaries based in Mountain View, California, and Singapore. Additional information about SanBio Group is available at <https://www.sanbio.com/en/>.

For more information, contact:

SanBio Co., Ltd.

Management Administration

Email: info@sanbio.jp